JP2009522369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522369A5 JP2009522369A5 JP2008549592A JP2008549592A JP2009522369A5 JP 2009522369 A5 JP2009522369 A5 JP 2009522369A5 JP 2008549592 A JP2008549592 A JP 2008549592A JP 2008549592 A JP2008549592 A JP 2008549592A JP 2009522369 A5 JP2009522369 A5 JP 2009522369A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- composition according
- transition period
- bisphosphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 230000007704 transition Effects 0.000 claims 12
- 229940122361 Bisphosphonate Drugs 0.000 claims 9
- 150000004663 bisphosphonates Chemical class 0.000 claims 9
- 238000009097 single-agent therapy Methods 0.000 claims 6
- 229940121682 Osteoclast inhibitor Drugs 0.000 claims 5
- 102000014128 RANK Ligand Human genes 0.000 claims 5
- 108010025832 RANK Ligand Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000010 osteolytic effect Effects 0.000 claims 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 4
- 229960004276 zoledronic acid Drugs 0.000 claims 4
- 241001529936 Murinae Species 0.000 claims 3
- 238000009175 antibody therapy Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 2
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229940009626 etidronate Drugs 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940089617 risedronate Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940019375 tiludronate Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75694406P | 2006-01-05 | 2006-01-05 | |
| US60/756,944 | 2006-01-05 | ||
| PCT/US2007/000405 WO2007081879A2 (en) | 2006-01-05 | 2007-01-04 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012186613A Division JP2012229271A (ja) | 2006-01-05 | 2012-08-27 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009522369A JP2009522369A (ja) | 2009-06-11 |
| JP2009522369A5 true JP2009522369A5 (enExample) | 2011-02-10 |
| JP5580535B2 JP5580535B2 (ja) | 2014-08-27 |
Family
ID=38219019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008549592A Active JP5580535B2 (ja) | 2006-01-05 | 2007-01-04 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
| JP2012186613A Pending JP2012229271A (ja) | 2006-01-05 | 2012-08-27 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012186613A Pending JP2012229271A (ja) | 2006-01-05 | 2012-08-27 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090246208A1 (enExample) |
| EP (2) | EP1984024A2 (enExample) |
| JP (2) | JP5580535B2 (enExample) |
| KR (1) | KR20080083187A (enExample) |
| CN (1) | CN101534858A (enExample) |
| AU (1) | AU2007205048B2 (enExample) |
| BR (1) | BRPI0706314A2 (enExample) |
| CA (1) | CA2636149A1 (enExample) |
| IL (1) | IL192568A0 (enExample) |
| RU (1) | RU2470665C2 (enExample) |
| TW (1) | TW200738262A (enExample) |
| WO (1) | WO2007081879A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| WO2010062399A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Csf1r extracellular domain fusion molecules and treatments using same |
| PT2949670T (pt) | 2009-12-10 | 2019-05-20 | Hoffmann La Roche | Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização |
| CA2789071C (en) * | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| WO2011107553A1 (en) | 2010-03-05 | 2011-09-09 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| CN107011438B (zh) | 2010-05-04 | 2020-11-20 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| AU2012285875B2 (en) | 2011-07-18 | 2016-11-10 | Morphosys Ag | Use of c-Fms antagonists |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN103044555B (zh) * | 2012-07-05 | 2016-08-31 | 雷克塞德（苏州）生物医药有限公司 | 包含cFms胞外片段的融合蛋白质及其制备方法和应用 |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CA2906394A1 (en) * | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| CN105121466A (zh) | 2013-04-12 | 2015-12-02 | 莫佛塞斯公司 | 靶向m-csf的抗体 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| RU2551622C1 (ru) * | 2014-02-20 | 2015-05-27 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения опухолей позвоночника |
| JP6964410B2 (ja) | 2014-06-23 | 2021-11-10 | ファイヴ プライム セラピューティクス インク | コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法 |
| LT3212670T (lt) | 2014-10-29 | 2021-02-10 | Five Prime Therapeutics, Inc. | Kombinuotasis vėžio gydymas |
| ES2843586T3 (es) | 2014-12-22 | 2021-07-19 | Five Prime Therapeutics Inc | Anticuerpos dirigidos contra CSF1R para tratar la SVNP |
| BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| RU2609871C1 (ru) * | 2015-08-10 | 2017-02-06 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Противоопухолевое средство |
| RU2631486C1 (ru) * | 2016-06-17 | 2017-09-22 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ получения противоопухолевого средства против метастазов костей в виде конъюгата белка-цитокина и аминобисфосфоната |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| EP3558360A1 (en) | 2016-12-22 | 2019-10-30 | F. Hoffmann-La Roche AG | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| KR20200051024A (ko) | 2017-09-13 | 2020-05-12 | 파이브 프라임 테라퓨틱스, 인크. | 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법 |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| DK0457804T3 (da) | 1989-02-10 | 1996-09-23 | Chiron Corp | M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE249840T1 (de) * | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6025146A (en) | 1995-06-05 | 2000-02-15 | Chiron Corporation | Identification of M-CSF agonists and antagonists |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| RU2153358C1 (ru) * | 1999-11-10 | 2000-07-27 | Центральный научно-исследовательский рентгенорадиологический институт МЗ России | Способ лечения остеолитических метастазов |
| US20030199531A1 (en) | 2001-07-19 | 2003-10-23 | Todd Wipke | YIGSR peptidomimetics and methods for using the same |
| JP2005516928A (ja) * | 2001-12-13 | 2005-06-09 | メルク エンド カムパニー インコーポレーテッド | 骨異常のためのビスホスホネート液体製剤 |
| MXPA05003318A (es) * | 2002-09-27 | 2005-09-12 | Zentaris Gmbh | Forma de administracion para peptidos farmaceuticamente activos con liberacion sostenida y metodo para la produccion de los mismos. |
| CA2505994A1 (en) * | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| PT2311873T (pt) * | 2004-01-07 | 2018-11-20 | Novartis Vaccines & Diagnostics Inc | Anticorpo monoclonal específico para m-csf e respetivos usos |
| JP5457671B2 (ja) * | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| NZ572072A (en) * | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
-
2007
- 2007-01-04 RU RU2008132150/15A patent/RU2470665C2/ru not_active IP Right Cessation
- 2007-01-04 KR KR1020087018238A patent/KR20080083187A/ko not_active Abandoned
- 2007-01-04 EP EP07716432A patent/EP1984024A2/en not_active Withdrawn
- 2007-01-04 WO PCT/US2007/000405 patent/WO2007081879A2/en not_active Ceased
- 2007-01-04 AU AU2007205048A patent/AU2007205048B2/en active Active
- 2007-01-04 EP EP13168106.6A patent/EP2705854A1/en not_active Withdrawn
- 2007-01-04 CN CNA2007800067993A patent/CN101534858A/zh active Pending
- 2007-01-04 JP JP2008549592A patent/JP5580535B2/ja active Active
- 2007-01-04 US US12/159,665 patent/US20090246208A1/en not_active Abandoned
- 2007-01-04 BR BRPI0706314-8A patent/BRPI0706314A2/pt not_active IP Right Cessation
- 2007-01-04 CA CA002636149A patent/CA2636149A1/en not_active Abandoned
- 2007-01-05 TW TW096100615A patent/TW200738262A/zh unknown
-
2008
- 2008-07-02 IL IL192568A patent/IL192568A0/en unknown
-
2012
- 2012-08-27 JP JP2012186613A patent/JP2012229271A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009522369A5 (enExample) | ||
| RU2008132150A (ru) | Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом | |
| JP2013500995A5 (enExample) | ||
| Xu et al. | Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? | |
| Cheer et al. | Zoledronic acid | |
| JP6067466B2 (ja) | 骨粗鬆症の治療および予防用のビスホスホン酸 | |
| CA2438848A1 (en) | Compositions for delivering bisphosphonates | |
| TWI706787B (zh) | 治療牙槽骨流失之方法 | |
| CZ20024134A3 (cs) | Farmaceutické prostředky obsahující bisfosfonáty pro léčení stavů s abnormálně zvýšeným kostním obratem | |
| RU2006140888A (ru) | Лекарственные формы на основе бисфосфонатов | |
| JP2006506365A5 (enExample) | ||
| RU2003133773A (ru) | Фармацевтическое применение бисфосфонатов | |
| HRP20161170T1 (hr) | Pripravak tekućine za dijalizu koji sadrži tvari za inhibiciju kristalizacije | |
| JP2005530819A5 (enExample) | ||
| JP2006500401A5 (enExample) | ||
| HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| Russell | Ibandronate: pharmacology and preclinical studies | |
| F. Barghash et al. | Pathophysiology of metastatic bone disease and the role of the second generation of bisphosphonates: from basic science to medicine | |
| Anghel et al. | Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease | |
| RU2003100503A (ru) | Способ введения бисфосфонатов | |
| Bartl et al. | Bisphosphonates (BPs) | |
| Bartl | Bisphosphonates (BP) and Denosumab | |
| JP2009508834A5 (enExample) | ||
| Adverse Drug Reactions Advisory Committee | Bisphosphonates and ocular inflammation | |
| Smith | SECTION 4 SUPPORTIVE CARE |